Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.38 |
| ▸ | CDK4 | P11802 | 5/20 | 0.35 |
| ▸ | CCND1 | P24385 | 5/20 | 0.35 |
| ▸ | CCND3 | P30281 | 5/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 5/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23130862 | 0.85 | OGA (0.35) | CHRM1OGAPSEN1PSEN2APH1B | |
| SCHEMBL6007557 | 0.85 | OGA (0.35) | CHRM1OGAPSEN1PSEN2APH1B | |
| SCHEMBL17440119 | 0.82 | CHRM1 (0.41) | CHRM1CDK4CCND1CCND3CDK6 | |
| SCHEMBL31734687 | 0.82 | CHRM1 (0.41) | CHRM1CDK4CCND1CCND3CDK6 | |
| SCHEMBL12099248 | 0.82 | CHRM1 (0.41) | CHRM1CDK4CCND1CCND3CDK6 | |
| SCHEMBL15932504 | 0.82 | OGA (0.38) | OGAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15932501 | 0.82 | OGA (0.38) | OGAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24015540 | 0.82 | OGA (0.38) | OGAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL25918400 | 0.81 | CHRM1 (0.33) | CHRM1CDK4CCND1CCND3CDK6 | |
| SCHEMBL19983195 | 0.81 | CYP11B2 (0.34) | OGAGABRA1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | CHRM1 4407/4885CDK4 1052/4885CCND1 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.